(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 June 2022 (23.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/129629 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61K 9/00* (2006.01)
A61P 11/06 (2006.01)

(21) International Application Number:
PCT/EP2021/086730

(22) International Filing Date:
20 December 2021 (20.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/127,903 18 December 2020 (18.12.2020) US

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; 151 85 Södertälje (SE).

(72) Inventors: **FITZGERALD, Mary**; c/o Pieris Pharmaceuticals GmbH, Zeppelinstrasse 3, 85399 Hallbergmoos (DE). **CLOSE, David Robert**; c/o AstraZeneca UK Limited, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA (GB). **GARDINER, Philip**; c/o AstraZeneca AB, 151 85 Södertälje (SE). **PALMÉR, Robert Alexander**; c/o AstraZeneca UK AB, 151 85 Södertälje (SE). **SAVOLAINEN, Marja Riikka**; c/o AstraZeneca AB, 151 85 Södertälje (SE). **GRACIN, Sandra**; c/o AstraZeneca AB, 151 85 Södertälje (SE). **AJMERA, Ankur**; c/o AstraZeneca AB, 151 85 Södertälje (SE).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: LIPOCALIN MUTEIN DRY POWDER FORMULATION FOR TREATMENT OF ASTHMA

(57) Abstract: The present invention relates to the treatment of asthma in a human subject by administering by oral inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Rα) lipocalin mutein, or a variant or fragment thereof, to said subject. The invention also relates to the dry powder formulation comprising the anti-IL-4 receptor alpha (IL-4Rα) lipocalin mutein, or a variant or fragment thereof.

WO 2022/129629 A1